The Two Faces of Relaxin in Cancer: Antitumor or Protumor?
The liver is one of the most common sites of metastatic disease from a variety of primary tumors including colorectal cancer, pancreatic ductal adenocarcinoma (PDAC), melanoma, breast cancer, and lung cancer. Moreover, metastatic disease to the liver is a leading cause of death in patients with malignancy. The liver has ample unique features favoring metastatic colonization by cancer (e.g. high blood flow, source of nutrients, etc.) especially the ability to induce immune tolerance. This tolerogenic capability is also important in cancer biology as tumors can commandeer this machinery, fostering a protumor and prometastatic microenvironment.1 However, what cells constitute this favorable metastatic niche and whether they can be therapeutically targeted remain open questions.